The following is an excerpt of a longer story.
Foundation Medicine and Memorial Sloan-Kettering Cancer Center this month announced a partnership that aims to bring genomics further into the clinic and help to translate molecular information into personalized cancer treatment.
Foundation Medicine, a molecular information company on the forefront of bringing comprehensive cancer genomic analysis to routine clinical care, has provided its first product, the FoundationOne™ assay, to clinicians since June 2012. It uses next-generation sequencing (NGS) to interrogate hundreds of cancer related genes from routine tumor samples. Test results are provided in a report that aligns detected mutations with potentially relevant treatment options and clinical trials.
Read the full story here: Moving Genomics Closer to the Clinic
